ストックスクリーナーアプリを入手
4.63
2.43%
0.11
アフターアワーズ：
4.63
前日終値:
$4.52
開ける：
$4.52
24時間の取引高:
74,675
Relative Volume:
0.27
時価総額：
$165.99M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
+5.71%
6か月 パフォーマンス:
-8.13%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$4.50
$4.64
1週間の範囲:
$4.47
$4.73
52週間の値動き範囲:
$2.88
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
BIOA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
4.63 | 165.99M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
151.54 | 70.46B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.78B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.69 | 45.15B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.01 | 19.16B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
298.16 | 13.56B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-12-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-21 | 開始されました | Citigroup | Buy |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-21 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioage Labs Inc (BIOA) 最新ニュース
Is BioAge Labs (NASDAQ:BIOA) Weighed On By Its Debt Load? - simplywall.st
Drugmaker Fights Claims Over 'Misleading' IPO Statements - Law360
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO - MSN
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Levi & Korsinsky Announces an Investigation on Behalf of BioAge Labs, Inc. (BIOA) Shareholders Who May Have Been Affected by Fraud - ACCESS Newswire
BioAge Labs, Inc.(NasdaqGS: BIOA) dropped from Russell 3000 Growth Index - MarketScreener
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Shareholders to Connect - ACCESS Newswire
BioAge Labs' APJ Agonism: A New Frontier in Combating Obesity and Heart Failure Comorbidities? - AInvest
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioAge Labs - ACCESS Newswire
BioAge to analyze 17,000 HUNT Biobank samples for aging research By Investing.com - Investing.com Nigeria
BioAge Labs to Profile Norwegian Biobank for Aging Drug Discovery - MarketScreener
BioAge Labs expands drug discovery platform with data from HUNT Biobank - TipRanks
BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank - Yahoo Finance
BioAge Labs Launches Initiative to Analyze Over 17,000 HUNT Biobank Samples for Drug Discovery in Aging-Related Diseases - Nasdaq
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review - marketscreener.com
Healthcare companies chase cures and capital in South Florida - Sun Sentinel
An Investigation Has Commenced on Behalf of BioAge Labs, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your BIOA Losses. - ACCESS Newswire
BioAge Labs Elects Directors at Annual Meeting - TipRanks
BIOA CLASS ACTION ALERT: BioAge Labs's 76% Stock Drop Triggers Securities Fraud Class Action; Contact BFA Law before March 10 Deadline - ACCESS Newswire
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Breakthrough Obesity Drug Pipeline: BioAge's New Treatment Doubles GLP-1 Weight Loss Effect - Stock Titan
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times
BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News
Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan
Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire
Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire
BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire
Bioage Labs Inc (BIOA) 財務データ
Bioage Labs Inc (BIOA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
8.43%
1.68%
大文字化:
|
ボリューム (24 時間):